Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda

April 2, 2019: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
  (Public Comment Prior to Board Action**)**

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**

- **Medical Director Update** **6:40 – 6:45**

- **Follow-up Items from Previous Meetings** **6:45 – 6:45**

- **RetroDUR/ProDUR** **6:45-7:00**
  - Introduce: Adherence to Anti-retroviral Therapy for HIV
  - Data presentation: Sildenafil Use in Patients without a PAH diagnosis

- **Clinical Update: Drug Reviews** **7:00-7:35**
  (Public comment prior to Board action)

  Abbreviated New Drug Reviews
  None at this time

  Full New Drug Reviews
  (Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)

  - Altreno® (tretinoin)
  - Plixda® (adapalene)
  - Arikayce® (Amikacin Liposome Inhalation Suspension)
  - Ilumya® (tildrakizumab- asmn)
  - Epidiolex® (cannabidiol)
  - Galafold® (migalastat)
  - Xofluza® (baloxavir marboxil)
  - Ztlido® (lidocaine topical)

- **New Managed Therapeutic Drug Classes** **7:35-7:45**
  (Public comment prior to Board action)
  - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:45 – 8:25**
  (Public comment prior to Board action)

- Anti-hypertensives: Angiotensin Modulators
- Anti-hypertensives: Beta Blockers
- Anti-hypertensives: Calcium Channel Blockers
- Antimigraine Agents, Triptans & CGRP Antagonist (NDR Ajovy® (fremanezumab- vfrm) and NDR Emgality® (galcanezumab- gnlm) included)
- Bile Salts
- Botulinum Toxins
- Lipotropics: Statins
- Lipotropics: Other

- **Review of Newly-Developed/Revised Criteria** **8:25 – 8:25**
  (Public comment prior to Board action)

- **General Announcements** **8:25 – 8:30**

  Selected FDA Safety Alerts

  FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
  https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm

  Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
  https://www.fda.gov/Drugs/DrugSafety/ucm631871.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20tofacitinib%20-%20Drug%20Information%20Update&utm_medium=email&utm_source=Eloqua

  FDA in Brief: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger
  https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm631875.htm?utm_campaign=FDA%20updates%20prescribing%20information%20for%20Chantix%20%28varenicline%29%20with%20data&utm_medium=email&utm_source=Eloqua

- **Adjourn** **8:30**